Conversion surgery for esophageal and esophagogastric junction cancer.

Autor: Shoji Y; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Kanamori K; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Koyanagi K; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan. kkoyanagi@tokai.ac.jp., Otsuka T; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Nakashima R; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Tajima K; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Ogimi M; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Ninomiya Y; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Yamamoto M; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Kazuno A; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Nishi T; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan., Mori M; Department of Gastroenterological Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara-City, Kanagawa, 259-1193, Japan.
Jazyk: angličtina
Zdroj: International journal of clinical oncology [Int J Clin Oncol] 2024 Dec; Vol. 29 (12), pp. 1777-1784. Date of Electronic Publication: 2024 Oct 22.
DOI: 10.1007/s10147-024-02639-4
Abstrakt: As a result of the recent advances in first-line treatment including chemotherapy, radiation therapy, targeted therapy, and immune checkpoint inhibitor immunotherapy (ICI) for locally advanced/metastatic initially unresectable esophageal and esophagogastric junction cancer, surgery aiming at cure after initial treatment, so-called "conversion surgery" has become more common in this field. Several studies have indicated encouraging survival outcomes for patients after conversion surgery with R0 resection. However, various issues, such the utility and the safety of conversion surgery remain unclear. In this review, we will focus on the surgical treatment for initially unresectable esophageal and esophagogastric junction cancer after first- or later- line treatment and review recent evidence regarding the safety and the efficacy of conversion surgery. Multidisciplinary treatment including surgery may serve as a novel treatment strategy for esophageal and esophagogastric junction cancer, thus provide a curative treatment option and potentially contribute to better prognosis for initially untreatable diseases.
Competing Interests: Declarations. Conflict of Interest: The authors have no conflict of interest to declare that are relevant to the content of this article.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: